Accordingly, in a recent retrospective analysis of BRAF-mutant myeloid neoplasms (AML, MDS, CMML, MPNs) over the span of ten years, Abuasab et al. identified a total of 48 patients, 18 of whom were diagnosed with BRAF-mutant AML (secondary AML in 66.7% [12/18]) of cases) [13]. The gene discussed is BRAF; the disease is myelodysplastic syndrome.